Login to Your Account

Neurovive walks the tightrope after its Ciclomulsion CIRCUS miss

By Marie Powers
News Editor

Monday, June 1, 2015
Neurovive Pharmaceutical AB was dangling from the high wire after reporting a top-line analysis of the phase III CIRCUS study of Ciclomulsion, which indicated the study missed the primary clinical endpoint in patients with ST-segment elevation acute myocardial infarction.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription